Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 6OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Leukemia, Prolymphocytic, T-Cell 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Lisaftoclax × 1 year × Clear all
NCT03913949 2026-05-01

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
74 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04501120 2026-04-29

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Ascentage Pharma Group Inc.

Phase 1/2 Recruiting
682 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05147467 2026-03-27

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
75 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06389292 2025-11-25

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Ascentage Pharma Group Inc.

Phase 3 Recruiting
486 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡